Cencora Inc. stock underperforms Monday when compared to competitors
Cencora Inc. (COR) stock fell 1.18% to $320.96 on Monday, underperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average both rose. This decline ended a three-day winning streak for the company's shares.
SIFY Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Sify Technologies Ltd (SIFY)'s financial performance, focusing on its revenue breakdown, profitability margins, and a comparison with competitors. Network-centric Services is SIFY's largest revenue contributor at 42.7%, while the company records a gross margin of 23.77% and a negative net margin of -2.84%. Comparatively, SIFY lags behind competitors COUR and LZ in gross margin.
DaVita's "Move It With Purpose" Sets Record Participation in Support of Global Health
DaVita's third annual "Move It With Purpose" (MIWP) event achieved record participation, with over 8,300 individuals logging 550,000 miles of activity across nearly 150 events. This initiative raised more than $750,000 for Bridge of Life, a nonprofit founded by DaVita, to support chronic disease prevention and treatment globally. Since 2007, DaVita has raised over $15 million for Bridge of Life, helping nearly 150,000 individuals in 34 countries.
Cencora Expands Retina Network As CFO Retirement Opens New Chapter
Cencora (NYSE:COR) has announced a binding agreement to acquire the retina division of EyeSouth Partners, aiming to reinforce its presence in ophthalmology-focused healthcare. Concurrently, the company's CFO, James F. Cleary, plans to retire by June 2026, prompting an executive search for his successor. These strategic moves—the acquisition to expand specialty care and the leadership transition—are set to shape Cencora's future direction in healthcare services.
Cencora Expands Retina Network As CFO Retirement Opens New Chapter
Cencora (NYSE:COR) is expanding its specialist healthcare offerings by acquiring the retina division of EyeSouth Partners, integrating it into its Retina Consultants of America network. This strategic move aims to strengthen its position in higher-complexity eye care services. Concurrently, CFO James F. Cleary announced his retirement, effective June 30, 2026, marking a leadership transition that investors will watch closely regarding capital allocation and financial strategy.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) shares rose 2.25% to $324.80 on Thursday, marking its third consecutive day of gains. This performance occurred on a mixed trading day, with the S&P 500 Index closing up 0.11% and the Dow Jones Industrial Average falling 0.13%.
Cencora will post quarterly results before the market opens May 6
Cencora, Inc. (NYSE: COR) announced it will release its Second Quarter Fiscal 2026 results on Wednesday, May 6, 2026, before market open. The company will host a conference call at 8:30 a.m. ET to discuss the results, featuring President & CEO Robert P. Mauch and Executive Vice President & CFO James F. Cleary. A live webcast and replay will be available on Cencora's investor relations website.
HF Advisory Group LLC Boosts Stock Holdings in Cencora, Inc. $COR
HF Advisory Group LLC significantly increased its stake in Cencora, Inc. (NYSE:COR) by 2,346% in the fourth quarter, acquiring an additional 58,228 shares, bringing its total to 60,710 shares valued at over $20.5 million. This makes Cencora the 20th largest position in HF Advisory Group's portfolio, representing about 0.8% of its total investments. Meanwhile, CEO Robert P. Mauch recently sold 5,096 shares for approximately $1.81 million, reducing his stake by 7.1%.
Cencora to Announce Fourth Quarter Fiscal 2025 Results on November 5
Cencora (NYSE: COR) announced it will release its fourth quarter fiscal 2025 results on November 5, 2025. The company will host a conference call and webcast to discuss these results, providing financial details and business updates. Investors can access the webcast and replay on Cencora's website.
Can CAH’s Unique Specialty Flywheel Approach Drive Sustainable Growth Over Time?
Cardinal Health (CAH) is implementing a comprehensive specialty strategy that integrates distribution, MSO platforms, and biopharma services to drive growth. This "specialty flywheel" positions CAH to capture a larger market share and sustain earnings growth, similar to strategies adopted by industry peers like McKesson and Cencora. CAH's stock has outperformed the industry year-to-date, and analysts project significant earnings growth for fiscal 2026.
Cencora Inc. Stock: Institutional Buying Signals Strength in Pharmaceutical Distribution Leader Amid
Cencora Inc. (NYSE:COR), a leading pharmaceutical distribution company, is attracting significant institutional investment, reflecting confidence in its stable market position and resilient business model. Recent SEC filings show notable increases in institutional holdings, with major investors like Vanguard Group and Viking Global Investors expanding their stakes. Analysts maintain a "Moderate Buy" consensus, projecting continued growth due to the company's operational efficiency, market leadership, and strategic focus on high-margin healthcare segments.
Press Release: Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release
Cencora (NYSE: COR) announced that it will release its second quarter fiscal year 2026 results on May 7, 2026. The company will also host a conference call and webcast to discuss these results at 8:30 a.m. ET on the same day. Investors can access the event via their website.
Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release
Cencora (NYSE: COR) announced it will release its Second Quarter Fiscal 2026 results on Wednesday, May 6, 2026, before the New York Stock Exchange opens. The company will host a conference call at 8:30 a.m. ET on May 6, 2026, with President & CEO Robert P. Mauch and Executive Vice President & CFO James F. Cleary. The live webcast will be available on Cencora's investor relations website, with a replay available for one year.
Cencora CFO James Cleary to Retire June 30, 2026
Cencora, Inc. announced that its Executive Vice President and Chief Financial Officer, James F. Cleary, will retire effective June 30, 2026. Cleary, 62, has been CFO since November 2018 and will assist in the transition while the company searches for a successor, both internally and externally. Cencora also reaffirmed its adjusted diluted earnings per share guidance for fiscal year 2026 in the range of $17.45 to $17.75.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) stock rose by 1.12% to $317.66 on Wednesday, outperforming the broader market indexes. The S&P 500 Index and the Dow Jones Industrial Average also saw gains, contributing to an overall favorable trading session. This marks the second consecutive day of gains for Cencora's stock.
Can CAH's Specialty Flywheel Strategy Unlock Long-Term Growth?
Cardinal Health's "specialty flywheel" strategy, integrating distribution, MSO platforms, and biopharma services, is projected to drive long-term growth by creating an interconnected ecosystem. This approach enhances manufacturer partnerships, streamlines product launches, and expands patient access, positioning Cardinal Health to capture a larger share of the specialty value chain. Peers like McKesson and Cencora are adopting similar strategies, indicating a broader industry shift towards specialty drugs and services as a key growth driver.
Can CAH's Specialty Flywheel Strategy Unlock Long-Term Growth?
Cardinal Health (CAH) is implementing a "specialty flywheel" strategy that integrates distribution, MSO platforms, and biopharma services to drive long-term growth. This approach creates a unified ecosystem that enhances credibility with manufacturers and secures recurring revenue streams. Other major distributors like McKesson (MCK) and Cencora (COR) are also focusing on similar integrated specialty strategies to capitalize on high-margin opportunities and long-term earnings expansion.
Cancer drug developers get more Actinium-225 as Cardinal Health expands
Cardinal Health (NYSE:CAH) has significantly expanded its Actinium-225 (Ac-225) production capacity at its Center for Theranostics Advancement in Indianapolis, quadrupling weekly output since late 2024. This expansion aims to meet the growing demand for novel targeted alpha cancer therapies, having already supported over 15 clinical trials worldwide. The company plans further capacity increases in 2026 to facilitate both clinical development and future commercial manufacturing of these critical oncology treatments.
Nisa Investment Advisors LLC Acquires 27,857 Shares of Cencora, Inc. $COR
Nisa Investment Advisors LLC significantly increased its stake in Cencora, acquiring 27,857 additional shares, bringing its total holdings to 104,962 shares valued at approximately $35.45 million. Concurrently, CEO Robert P. Mauch reduced his position by selling 5,096 shares for $1.81 million. Cencora successfully beat quarterly EPS estimates, reported $85.93 billion in revenue, and maintains a "Moderate Buy" analyst rating with an average target price of $403.17.
Bourgeon Capital Management LLC Invests $2.74 Million in Cencora, Inc. $COR
Bourgeon Capital Management LLC recently acquired a new stake in Cencora, Inc. (NYSE:COR), purchasing 8,124 shares valued at approximately $2.74 million in the fourth quarter. This move is part of broader institutional interest, with several other hedge funds and institutional investors also modifying their holdings in Cencora during the second quarter. The company has an average rating of "Moderate Buy" from analysts, with an average target price of $403.17, after some analysts increased their price objectives and upgraded their ratings.
Cencora Inc. stock rises Tuesday, still underperforms market
Shares of Cencora Inc. (COR) rose 1.36% to $314.14 on Tuesday, ending a four-day losing streak. Despite the increase, the stock underperformed the broader market, which saw significant gains with the S&P 500 Index rising 2.91% and the Dow Jones Industrial Average rising 2.49%.
Spire Wealth Management Raises Stock Position in Cencora, Inc. $COR
Spire Wealth Management significantly increased its stake in Cencora, Inc. (NYSE:COR) by 221.6% in the fourth quarter, now holding 5,753 shares valued at approximately $1.94 million. This comes as Cencora reported Q4 EPS of $4.08, beating estimates, and revenue of $85.93 billion, slightly below expectations. The stock maintains a "Moderate Buy" consensus rating from analysts with an average price target of $403.17, despite high institutional ownership and a recent insider share sale by CEO Robert P. Mauch.
Allspring Global Investments Holdings LLC Sells 40,638 Shares of Cencora, Inc. $COR
Allspring Global Investments Holdings LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 9.6% in the fourth quarter, selling 40,638 shares and now holding 383,068 shares valued at approximately $129.8 million. Cencora reported strong Q4 EPS of $4.08 on $85.93 billion in revenue, exceeding analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts with a mean price target of $403.17, and also recently declared a quarterly dividend of $0.60 per share.
Assessing Cencora (COR) Valuation After Recent Share Price Weakness And Premium P/E Ratio
Cencora (COR) has recently experienced share price weakness, with negative returns over the past week, month, and three months, despite strong longer-term performance. While Simply Wall St's narrative suggests the stock is 23.4% undervalued with a fair value of $407.92, its current P/E ratio of 37.4x is higher than the US Healthcare industry average, indicating a premium and less room for error if growth falters. Investors are encouraged to consider the full picture, including key rewards and warning signs, and explore other investment opportunities beyond Cencora.
Did Cardinal Health's (CAH) New Chair and Urology Deal Just Reframe Its Healthcare Partnership Strategy?
Cardinal Health recently appointed Patricia A. Hemingway Hall as the new Chair of its Board, succeeding Gregory B. Kenny. This leadership change, coupled with a recent urology-focused acquisition, is seen as continuity in the company's strategy to expand into higher-margin specialty businesses. The article suggests these moves are crucial for Cardinal Health to improve profitability amid thin margins and regulatory pressures, aiming for $317.2 billion in revenue and $2.6 billion in earnings by 2029 with a projected fair value of $249.60.
Cencora, Inc. (COR) Signs Binding Agreement to Expand Retina Network With EyeSouth Acquisition
Cencora, Inc. (COR) has signed a binding agreement to acquire the retina division of EyeSouth Partners for $1.1 billion, aiming to expand its Retina Consultants of America network. This acquisition will integrate EyeSouth's regional physician network, enhance advanced retina care delivery, and reinforce Cencora's commitment to community-based ophthalmologists. Additionally, Cencora reaffirmed its fiscal 2026 adjusted diluted EPS outlook and announced the retirement of CFO James F. Cleary.
Donaldson Capital Management LLC Has $46.31 Million Stock Holdings in Cencora, Inc. $COR
Donaldson Capital Management LLC significantly increased its stake in Cencora (NYSE:COR) by 1,955.8% in Q4, holding 137,099 shares valued at $46.31 million. Institutional investors collectively own about 97.52% of Cencora's stock. Analysts generally rate Cencora as a "Moderate Buy" with an average target price of $403.17, following a recent EPS beat and a quarterly dividend announcement.
Cencora, Inc. $COR Shares Sold by Wedge Capital Management L L P NC
Wedge Capital Management L L P NC reduced its stake in Cencora, Inc. (NYSE:COR) by 7.9% in the fourth quarter, selling 7,014 shares but still holding 81,395 shares valued at $27.49 million. This sale occurred despite several other institutional investors, such as Norges Bank and Marshall Wace LLP, significantly increasing their positions in Cencora. Additionally, Cencora's CEO, Robert P. Mauch, sold 5,096 shares for approximately $1.81 million, although company insiders still own 0.38% of the stock.
Cencora, Inc. $COR Shares Sold by Waycross Partners LLC
Waycross Partners LLC reduced its holdings in Cencora (NYSE:COR) by 33.3% in Q4 2025, selling 5,000 shares and now owning 10,000 shares valued at $3.38 million. Concurrently, CEO Robert P. Mauch sold 5,096 shares for $1.81 million, decreasing his ownership by 7.1%. Despite this, analysts largely maintain bullish ratings with an average target price of $403.17, significantly above the current share price near $312.
MCK (McKesson) Enterprise Value : $112,223 Mil (As of Mar. 28, 2026) ***
This article provides a detailed analysis of McKesson Corp's (NYSE:MCK) Enterprise Value as of March 28, 2026, which stands at $112,223 Million. It breaks down various valuation ratios such as EV-to-EBIT, EV-to-EBITDA, EV-to-Revenue, EV-to-OCF, and EV-to-FCF, explaining their calculations based on the company's financial data up to December 2025. The article also notes that McKesson is considered "Modestly Overvalued" by GuruFocus, with a GF Score of 82/100 and two warning signs for investors.
Cencora Inc. stock outperforms competitors despite losses on the day
Shares of Cencora Inc. (COR) fell 1.75% to $312.45 on Friday, marking its third consecutive day of losses. Despite the decline, the stock outperformed the broader market, which saw the S&P 500 Index and Dow Jones Industrial Average both fall by over 1.6%.
Matrix Trust Co Invests $1.40 Million in Cencora, Inc. $COR
Matrix Trust Co has acquired a new stake of 4,153 shares in Cencora (NYSE:COR) valued at approximately $1.40 million during the fourth quarter. This investment highlights significant institutional interest, as major funds like Vanguard, State Street, and JPMorgan have also increased their positions in the healthcare services and pharmaceutical distribution company. Cencora, with a market cap of $61.86 billion, has shown strong financial performance, beating EPS expectations last quarter and paying a quarterly dividend, while analysts maintain a "Moderate Buy" rating with an average price target of $403.17.
Synergy Asset Management LLC Cuts Stake in Cencora, Inc. $COR
Synergy Asset Management LLC significantly reduced its stake in Cencora, Inc. by 49.2% in the fourth quarter, selling 15,900 shares and retaining 16,393 shares valued at approximately $5.54 million. Despite this reduction, institutional investors collectively own 97.52% of Cencora, with major firms like Vanguard and State Street increasing their positions. Analysts maintain a "Moderate Buy" consensus rating for Cencora, with an average target price of $403.17, noting the company's recent EPS beat and a 0.8% annual dividend yield.
MCK (McKesson) Net Income From Continuing Operations : $4,550 Mil (TTM As of Dec. 2025)
This article reports that McKesson Corp (NYSE:MCK) had a Net Income From Continuing Operations of $4,550 million for the trailing twelve months (TTM) ended December 2025. GuruFocus rates MCK with a GF Score of 82/100 and a GF Value of $776.81, considering it modestly overvalued at its current price of $860.16. The net income from continuing operations represents the firm's earnings from ongoing business activities, excluding extraordinary and non-recurring items.
Vanguard discloses zero Cencora holdings (NYSE: COR) after internal realignment
The Vanguard Group has filed an Amendment No. 20 to a Schedule 13G/A, reporting zero beneficial ownership in Cencora Inc (NYSE: COR) common stock, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, which led certain Vanguard subsidiaries and business divisions to report their holdings separately. The filing clarifies a reporting mechanics disclosure rather than signaling a market action.
Boston Scientific Corp Stock (BSX) Moved Up by 3.66% on Mar 26: Key Drivers Unveiled
Boston Scientific (BSX) stock climbed 3.66% on March 26, driven by positive analyst sentiment, anticipation of WATCHMAN device clinical trial results, and the strategic acquisition of Penumbra for $14.5 billion. Analysts maintain "Strong Buy" ratings with price targets up to $120, reflecting confidence despite an ongoing class-action lawsuit. The upcoming CHAMPION-AF data presentation and investor event are key immediate catalysts.
Cencora to buy EyeSouth Partners' retina division in $1B deal
Cencora, Inc. is set to acquire EyeSouth Partners' retina division for $1.1 billion, expanding its Retina Consultants of America (RCA) network. RCA, in which Cencora holds an 85% interest, is a significant management service organization for retina specialists and boasts a large retina research program. This acquisition will integrate EyeSouth's retina-focused practices into RCA, providing them access to an extended network and clinical trial opportunities, with the deal expected to close by September 30.
Cencora Inc. stock underperforms Thursday when compared to competitors
Cencora Inc. (COR) stock declined by 2.17% on Thursday, closing at $318.03, continuing its losing streak for a second consecutive day. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines. The article attributes the content to MarketWatch Automation, supported by Dow Jones and FactSet data.
McKesson Corporation stock faces margin pressures amid US prescription drug pricing reforms and dist
McKesson Corporation faces margin pressures due to US prescription drug pricing reforms and generic pricing erosion, despite volume gains in specialty drugs and strategic acquisitions in oncology and healthcare IT. The company's Q4 earnings beat expectations, but management warns of continued generic pricing headwinds into fiscal 2026. McKesson aims to mitigate these challenges through diversification and operational efficiency, remaining a stable healthcare investment with a conservative outlook.
Cencora Inc. stock faces uncertainty amid Medicaid managed care pressures and management shifts
Cencora Inc., formerly AmerisourceBergen, is grappling with uncertainties stemming from Medicaid managed care pressures and potential management changes. Despite steady revenue growth driven by specialty pharmaceuticals, softening demand signals from government payers and policy shifts affecting drug pricing are impacting the pharmaceutical distributor. Investors are closely monitoring Cencora's operational resilience, supply chain efficiency, and its ability to navigate regulatory challenges as it plays a critical role in the US drug supply chain.
Is It Time To Reassess Cencora (COR) After The Recent Share Price Pullback
Cencora (COR) has recently experienced a share price pullback, raising questions about its current valuation despite strong multi-year returns. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 45.6%, estimating an intrinsic value of $601.42 per share against a market price of $326.91. However, its Price-to-Earnings (P/E) ratio of 39.13x is above the industry average and Simply Wall St's Fair Ratio, indicating it could be modestly overvalued by this metric.
Why STAAR Surgical (STAA) Stock Is Trading Up Today
STAAR Surgical (STAA) stock rose 3.7% after Cencora announced the acquisition of EyeSouth Partners' retina business for $1.1 billion. While STAAR Surgical was not directly involved, the deal strengthened investor confidence in the broader ophthalmology sector. Despite the positive news, the company's shares remain volatile, having experienced a significant drop earlier in the year after a proposed acquisition by Alcon fell through.
Cencora Expands Retina Network With EyeSouth Deal And Earnings Focus
Cencora is acquiring the retina business of EyeSouth Partners, integrating it into its majority-owned Retina Consultants of America. This move expands Cencora's reach in ophthalmology and is expected to be accretive to adjusted earnings, subject to regulatory approval. The acquisition further solidifies Cencora's focus on specialty care services, though investors should consider integration risks and regulatory factors.
Cencora Expands Retina Network With EyeSouth Deal And Earnings Focus
Cencora (NYSE:COR) is expanding its ophthalmology services by acquiring the retina business of EyeSouth Partners, which will integrate into its existing Retina Consultants of America network. This strategic acquisition is expected to be accretive to adjusted earnings, subject to regulatory approval, and further deepens Cencora's presence in specialty healthcare. The move aligns with Cencora's strategy of growing its specialty and rare-disease services through acquisitions, aiming for long-term earnings resilience despite recent share price volatility.
Health Insurance Providers Stocks Q4 In Review: Centene (NYSE:CNC) Vs Peers
This article reviews the Q4 earnings of several health insurance providers, including Centene (NYSE:CNC), Clover Health (NASDAQ:CLOV), Molina Healthcare (NYSE:MOH), Alignment Healthcare (NASDAQ:ALHC), and Cencora (NYSE:COR). It highlights Centene's mixed quarter with a revenue beat but missed full-year guidance, Clover Health's strong revenue growth, Molina Healthcare's softer quarter with missed guidance, Alignment Healthcare's mixed results, and Cencora's slight revenue miss. The sector as a whole experienced a slower Q4, with revenues beating estimates by 0.8% collectively, yet share prices have declined by an average of 11.9% since earnings reports.
Cencora Inc. stock outperforms competitors on strong trading day
Cencora Inc. (COR) shares rose by 2.08% to $327.27 on Tuesday, despite a general market downturn where the S&P 500 Index fell 0.37% and the Dow Jones Industrial Average dropped 0.18%. This performance broke a two-day losing streak for Cencora. The article highlights Cencora's stock strength against a weak market backdrop.
Cencora to buy EyeSouth’s retina business for $1.1B
Cencora has agreed to acquire EyeSouth Partners' retina business for $1.1 billion, continuing its expansion into specialty medical services. The acquisition will integrate EyeSouth's physicians into Cencora's Retina Consultants of America management services organization, aiming to bolster its ophthalmology market presence and capitalize on biosimilar opportunities. This deal follows Cencora's previous acquisition of RCA and McKesson's purchase of PRISM Vision Holdings, indicating a growing trend of drug distributors investing in retina MSOs.
COR to Broaden Retina Consultants of America Through $1.1B EyeSouth Acquisition
Cencora, Inc. (COR) has agreed to acquire the retina operations of EyeSouth Partners for $1.1 billion, aiming to strengthen its Retina Consultants of America (RCA) platform. This acquisition will expand Cencora’s presence in the growing ophthalmology sector, integrate EyeSouth’s retina specialists into RCA, and enhance clinical care, research, and operational efficiencies. The deal is expected to have a modest positive impact on Cencora's adjusted diluted EPS within the first year, solidifying its long-term growth strategy in retina care.
UBS reiterates Cencora stock rating on EyeSouth retina deal
UBS has reiterated a Buy rating and a $410.00 price target on Cencora Inc. following its $1.1 billion acquisition of EyeSouth Partners' retina business. This acquisition is expected to be slightly accretive to adjusted earnings per share and synergistic with Cencora's existing retina care business, capitalizing on high drug usage in ophthalmology. Other analysts like Evercore ISI and BofA Securities have also weighed in on the deal and the surprise retirement of Cencora's CFO, James Cleary.
Kultura Brands (OTC:LTNC) Accelerates National Momentum With Cencora Marketplace Spring & Summer Growth Acceleration Program
Kultura Brands Inc. (OTCID:LTNC) announced its expanded participation in Cencora's Spring & Summer Growth Acceleration Program, aiming to accelerate the adoption of its Thirst Responder and other brands across U.S. pharmacies. This initiative coincides with the company's efforts to scale national distribution and strengthen retail partnerships. The program, which runs through April, is designed to help pharmacies prepare for key seasonal demands, and Kultura Brands expects it to drive increased product trial, retail penetration, and continued growth in 2026.
